To assess whether this elevated CD38 expression in tumor cells conferred any therapeutic benefits, we conducted a combination therapy study involving αCD38 antibody and panobinostat using our mouse model of CTCL. This evidence concerns the gene CD38 and primary cutaneous T-cell non-Hodgkin lymphoma.